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The discovery of novel markers for breast cancer (BC) has been recently relied on antibody combinatorial
libraries and selection through phage display. We constructed a recombinant Fab library, and after selec-
tions against BC tissues, the FabC4 clone was thoroughly investigated by immunohistochemistry in 232
patients with long-term follow-up. The FabC4 ligand was determined by mass spectrometry. The FabC4
expression was associated with younger age, lack of progesterone receptor, higher histological grades and
non-luminal subtypes, and it also identiﬁed a subset of good prognostic triple-negative BCs, possibly tar-
geting a conformational epitope of Cytokeratin-10 (CK10). This new CK10-epitope speciﬁc antibody may
open new possibilities in diagnostic and therapeutic strategies.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Breast cancer (BC) is the most frequent malignant tumor of wo-
men in North America [1], is the second leading cause of death,
after lung cancer [2] and the parameters currently available are
not sufﬁcient to capture its individual complexity [3]. During the
past decade, several genomics-based techniques have signiﬁcantly
improved the molecular characterization of breast tumors, and
these approaches have expanded the BC classiﬁcation, which re-
sulted in new clinical diagnostic tests [4]. However, the heteroge-
neous nature of this disease, encompassing a wide variety of
pathological entities in which 40% of the patients still succumb,
highlights the need for new therapeutic strategies and identiﬁca-
tion of new targets [3,5].It is known that malignant transformation of cells often causes
dramatic changes in the expression of cell surface molecules [6],
and antibodies have proven to be excellent high-afﬁnity protein-
based ligands to detect such alterations [7]. Antibody therapy of-
fers great promise for cancer treatment, and several antibodies
have been approved in clinical settings. Among them, the anti-
HER-2 extracellular domain humanized monoclonal antibody,
trastuzumab, is considered to be the prototype of a successful tar-
get drug. It has been widely used in the last decade for the treat-
ment of HER-2 positive BCs in the neoadjuvant, adjuvant and
metastatic settings [8–10].
Monoclonal antibodies (mAb) are generated by either hybrid-
oma or by combinatorial antibody technologies [6], with libraries
that can be naïve, semi-synthetic, synthetic and fully synthetic
[11]. Recombinant antibodies present several advantages, such
as: production in recombinant bacteria, yeast or plant, immuniza-
tion is not required, and intrinsic properties such as immunogenic-
ity, afﬁnity, speciﬁcity and stability can be improved by various
mutagenesis technologies [12]. Thus, the construction and selec-
tion of antibody combinatorial libraries expressed on ﬁlamentous
Fig. 1. Schematic outline of the construction the Fab repertoire using phage display. Total RNA was ﬁrst isolated (A) and IgG and IgM heavy chain were ampliﬁed including
ﬁve VH families (B) followed by Vj (C), CH and Cj (D) ampliﬁcations. The puriﬁed amplicons were assembled in a second round of PCR (E) which was assembled to generate
the human Fab fragment (F). After SﬁI digestion and ligation of the Fab to the phagemid, the ligated vector was induced into E. coli. The culture was infected by VCSM13 helper
and displayed as fusion to pIII coat protein.
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antigen-speciﬁc ligands with higher afﬁnity and without cross-
reactivity, due to their unequal, expanded and diverse antibody
repertoire, with important applications in diagnosis and therapy
[8–10].The selected phage displayed antibody combinatorial fragments
mimic immune selection and maturation of antibodies, providing
the most robust, versatile and wide spread selection method in
the past decade [11,13]. A crucial advantage of this technology
is the direct link between the experimental phenotype and its
Table 1
Patients’ characteristics (N = 232).
Variable Patients
N. %
Age (years)
Median (range) 54 (25–86)
Menopausal status
Premenopausal 98 42
Premenopausal 134 58
Lymph node status
cN0 74 32
cN1–3 158 68
Tumor stage
cT1 19 8
cT2 101 43
cT3 48 21
cT4 64 28
Histological grading
G1 44 19
G2 127 55
G3 61 26
ER status
Negative 84 36
Positive 134 58
NA 14 6
PgR status
Negative 156 67
Positive 65 28
NA 11 5
HER-2a
Negative 166 72
Positive 22 9
NA 44 19
Breast cancer subtypesb
Luminal 148 64
HER-2-enriched 16 7
Triple negative 48 21
NA 20 8
Chemotherapy
No 39 17
Yes 193 83
Radiation therapy
No 39 17
Yes 193 83
Hormone therapy
No 126 54
Yes 106 46
Abbreviations: NA = not available; ER, estrogen receptor; HER2, human epidermal
growth factor receptor 2; PgR, progesterone receptor.
a HER2 status was considered as positive (score 3+) and negative (score 0–1+);
scores 2 + were excluded from the analyses.
b Cases were classiﬁed as luminal (ER + and/or PgR + with HER-2-), HER2-enri-
ched (ER-/PgR-/HER2+), and triple negative (ER-/PgR-/HER2-).
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binders into optimized molecules [14,15], as shown against differ-
ent antigens [12,13,16,17], including melanoma [18], colorectal
[19] and prostate [6,20,21] cancer proteins.
In this study, we have constructed a Fab combinatorial antibody
library on M13 phage from transcripts of BC patients. The choice of
the Fab format was based on the notion that monomeric appear-
ance of the Fab permits the rapid screening of large numbers of
clones [16]. Additionally, Fab antibodies are more stable and ame-
nable to retaining the natural folding and binding characteristics,
governed by afﬁnity rather than avidity, avoiding such problems
presented in multimeric scFv libraries [21]. While genetic and
epigenetic changes in genes that regulate mammary epithelial cell
proliferations, survival, polarity and/or differentiation are probable
initiators of breast carcinogenesis, several lines of evidenceindicate that stromal cell responses may promote cancer progres-
sion and metastasis [22]. To identify these probable factors in-
volved in BC development in stromal cells, we have analyzed the
library diversity, and selected a target-speciﬁc antibody clone,
FabC4, against antigens from tumor breast tissues. Its applicability
in a cohort of BC patients with long-term follow-up was evaluated
in order to associate its expression with clinical-pathological char-
acteristics and survival.2. Materials and methods
2.1. Study design and sample collection for library construction
This Project was carried out from 2008 to 2009 at the Nanobiotechnology Lab-
oratory of the Federal University of Uberlandia (UFU) together with the Obstetrics’
Services of University Hospital. The study protocol was approved by the UFU Re-
search Ethics Committee (N. 176/2008), and an informed consent was obtained
from all participants. All peripheral blood leukocytes (PBL) and tissue samples were
obtained from patients that live in Uberlandia – MG (Brazil). The ethnic background
was not recorded since the Brazilian population is highly heterogeneous and mixed.
Peripheral blood samples were collected before surgery in a vaccutainer™ tube con-
taining K2EDTA 7.2 mg, and maintained at 4 C.
To construct the Fab combinatorial library, we have obtained PBL from 20 wo-
men patients (mean age of 54 years) with ductal invasive BC grade I (5%), grade II
(90%) and grade III (5%), submitted to mastectomy with no preoperative chemo-
therapy, radiation or hormonal therapy. Breast tissues from three patients diag-
nosed with ductal invasive BC (two classiﬁed as grade II and one as grade III,
mean age of 52 years, mastectomized, and presenting more than 80% of malignant
tissue) were used to perform selection of the phage displayed antibody library. Nor-
mal tissues from patients submitted to breast reduction surgery (mean age,
50 years), and with no familial history of breast cancer, were collected under an in-
formed consent and were classiﬁed as a control group.2.2. RNA extraction and ﬁrst-strand cDNA synthesis
Total RNA was extracted from PBL of each patient by Guanidine Isothiocyanate
extraction method [23] with minor modiﬁcations. The RNA concentration and quality
were analyzed in a 1.2% agarose gel electrophoresis stained with ethidium bromide
andbyabsorbance readingsat260and280 nm.RNAswerepooled inequimolar concen-
trations andused to synthesize theﬁrst-strand cDNA. Fourmicrograms of this RNApool
were mixed with 10 pmol of speciﬁc primers for ampliﬁcations of the heavy and light
chain immunoglobulins [22] that were submitted to 70 C for 10 min. The reverse tran-
scription was performed with 10U of SuperScriptII Reverse Transcriptase (Invitrogen),
5XSuperScript-RTBuffer, 10UofRNAse inhibitor (Invitrogen)and200 lMofeachdNTP,
which was incubated at 42 C for 60min. The reaction was terminated by heating at
70 C for 15 min.2.3. Construction of human Fab combinatorial library
First-strand cDNA derived from PBL of BC patients was used to generate the Fab
genes repertoire by PCR reactions as described elsewhere [26]. Brieﬂy, two sets of
six PCR ampliﬁcations were performed by using sense primers for VH fragments,
combined with g or m anti-sense primers. Similarly, VL gene fragments were
obtained by using four sense primers, covering the whole kappa repertoire. These
primers were used with a single 30 oligonucleotide targeting the kappa constant re-
gion (Cj). Primers used in this ﬁrst PCR reaction were designed for the posterior
assembly of the heavy chain (Fd) fragment in a second PCR reaction. For this
purpose, g and m VH fragments were fused to a g constant region (CH1). The com-
plete light chains were constructed by fusing VLs to a Cj fragment in another PCR
reaction. Fd fragments and kappa light chains were ultimately shufﬂed in a ﬁnal
overlap recombinant PCR. Cloning procedures, preparation of phage and the con-
struction of the Fab library were performed as described elsewhere [24], and dem-
onstrated in Fig. 1.2.4. Library size
A total of 7.4 lg of DNA was electroporated into the XL1-Blue E. coli strain to
generate the Fab phage library. After electroporation, the cuvette was ﬂushed with
3 mL of SOC medium (contains bactotryptone, bactoyeast, NaCl, KCl, MgCl2 and glu-
cose) and transformed cells were incubated for 1 h at 37 C before spreading on LB
agar/carbenicillin (50 lg/mL) plates. Then, the plate was incubated overnight at
37 C. The size of the library was determined by 10-fold serial dilutions of the trans-
formed cells.
Fig. 2. VH and VL repertoire of non-ampliﬁed original Fab library. The graph shows the frequency of VL (A) and VH (B) gene segment family usage (%). The sequences were
aligned to their closest germline, using the Ig-Blast to identify the V family.
Fig. 3. Characterization of selected clones after induction by IPTG. The presence of soluble Fab fragments was evaluated by anti-HA antibody, which recognized the
hemaglutin tag fused to VH chain. Slot blot analysis demonstrated Fab expression in 98% of selected clones (A). Clone 84 corresponds to pComb3X vector supernatant without
Fab fragment. SDS–PAGE (B) and Western-Blot assays (C) was performed to conﬁrm the presence of human Fab in culture supernatants which corresponds to 28 kDa. M
shows Prestained SDS–PAGE Standards, Broad Range (Bio-Rad) and C1–C4 shows randomly selected clones from expression plates.
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Selection of phage particles displaying speciﬁc Fab fragments was performed
directly in fresh tissues, right after the surgery. The subtractive selection was per-
formed in tissues from patients submitted to mammoplasty, neither with benign
mammary disease nor with familial history of BC. For each round of selection, phage
particles were ampliﬁed. For this purpose, 50 lL of XL1-Blue electrocompetent cells
were inoculated in 50 mL of super broth (SB) medium containing tetracycline
(10 lg/mL). The culture was shaken until OD600g = 1.0 and infected by 50 lL of
phage display antibody library incubated 1 h at 37 C. The infectious phage titer
was determined by adding 1 lL and 10 lL on E. coli culture in Luria Broth supple-
mented with 20 lg/mL of carbenicillin and 2% glucose, which were shaker-incu-
bated at 37 C for 16 h. The carbenicillin concentration was then increased to
50 lg/mL. After an additional 1-h incubation at 37 C, cultures were centrifuged
at 3000g for 10 min at room temperature and ressuspended in 500 mL of pre-
warmed SB medium supplemented with tetracycline and carbenicillin, as previ-
ously described, and 2 mL of VCSM13 helper phage (>1  1012 PFU/mL). After 2-h
incubation at 37 C, cultures were supplemented with 70 lg/mL of kanamycin,
and further incubated overnight at 37 C. The phages were precipitated as previ-
ously described, and used in the next selection cycle, following a total of three
rounds of selection. After the third cycle, selected colonies were ampliﬁed and in-
duced for soluble production of Fab, followed by phagemid DNA extraction. For
each selection cycle, normal tissues were placed in a microtube containing 1X
PBS (phosphate-buffered saline) until processing. After washing with PBS/2% BSA,
tissues were incubated with 50 lL of ampliﬁed library with PBS/2% BSA in a ﬁnal
volume of 500 lL, and incubated at 4 C for 1 h. The unbound phages in the super-
natant were transferred to a microtube with a fresh microdissected breast cancer
tissue with the addition of Tween-20 to a ﬁnal concentration of 0.05%, andincubated at 4 C for 2 h. The unbound viral particles were discarded, and the tu-
mor tissue was washed 10 times with PBST (PBS/Tween-20 0.1%) by centrifuga-
tion at 3000g for 2 min. The bound phages were submitted to a competitive
elution transferring the tissue to an XL1-Blue electrocompetent bacterial culture
in OD600g = 1.0 for infection, phage ampliﬁcation and titration.
2.6. Soluble Fab antibodies production
Individual selected clones from the third selection round were grown overnight
at 37 C in deep-well plates containing 1 mL of SB medium supplemented with
50 lg/mL carbenicillin and 2% glucose in each well. Phagemids without Fab inserts
were grown in two wells, as negative controls. In a new deep-well plate containing
supplemented SB medium, 50 lL of each clone was transferred and incubated by
shaking at 37 C. After reaching the absorbance (OD600) equal to 1.0, the culture
was centrifuged at 3000g for 10 min at 4 C. Bacteria were resuspended in
1.5 mL SB medium and induced with 2.0 mM IPTG overnight at 30 C (no more than
18 h). The supernatant containing the Fab was obtained by 3000g centrifugation
for 20 min and was directly subjected to Immunoblot and ELISA analyses.
2.7. Slot-blot, SDS–PAGE and Immunoblot
Slot-blot analysis was performed using the induced culture supernatants of ran-
domly chosen selected clones. Ten microliters of each selected clone supernatant
was applied to a nitrocellulose membrane (Hybond ECL, Amersham Biosciences).
The membrane was dried at room temperature, blocked with BSA3% (w/v) in PBS
for 1 h at room temperature and washed 3 times with PBST 0.05%. The soluble anti-
body was detected with 1:5000 diluted HRP-conjugated rat anti-HA (Roche Applied
Fig. 4. Evaluation of the binding selectivity for the induced clones using a pre-screening ELISA in total protein extracted from normal, benign and tumor tissue samples.
Absorbance in 492 nm is described in panel A with 8 reactive clones obtained from supernatant of bacterial medium after IPTG induction. ANOVA test demonstrated that all
clones discriminated breast cancer from benign samples. FabC4 clone was selected for additional procedures, based on its reactivity ratio between cancer/benign and cancer/
control (B), which was higher than the other clones. ELISA assay between the recombinant CK10 and the FabC4 antibody for antigen validation (C). Absorbance was
signiﬁcantly different between the three groups of proteins extracted from BC; BBT and N patients. BC protein did not differed from CK10 absorbance and was positive for
HPLC-puriﬁed FabC4 detection. The other groups presented signiﬁcantly lower absorbance compared to CK10 recombinant protein. BC: breast cancer; BBT: benign breast
tumor; N: normal tissue. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
Fig. 5. Mass spectrometry sequencing for FabC4 target detection comparing breast cancer and benign tissues. It was detected three potential targets: CK1 (A), CK9 (B) and
CK10 (C). According to peptide matches and comparing the two groups CK10 was characterized as FabC4 target. In yellow: peptide matches. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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tection. After 2 h of incubation at room temperature the membrane was washed
with PBST and visualized using 3,30-diaminobenzidine (DAB) (Sigma Aldrich). In or-
der to conﬁrm the presence of Fab fragments, four clones were randomly selected,
and 30 lL of the supernatant were separated by 12.5% SDS–PAGE and blotted onto
0.22 lm nitrocellulose membrane for Western Blot analysis, which was performed
according to the slot-blot assay.2.8. ELISA screening of selected clones
In order to investigate BC antigen recognition, Immuno 96 Micro-Well™ (Nunc,
Denmark) plates were coated with 1 lg/well of total protein extracted from pools of
normal, benign and tumor breast tissues in 100 lL of sodium bicarbonate buffer pH
7.4 (NaHCO3), at 4 C overnight. The plates were washed 3 times with PBST 0.05%
and blocked with 5% slim milk-PBS for 3 h at room temperature. After washes,
Fig. 6. Immunoafﬁnity of FAbC4 against breast cancer tissue antigens. (A) Invasive adenocarcinoma showing striking labeling in the nucleus and cytoplasm from ductal cells.
(B) Moderate cytoplasmic immunoreactivity of ductal epithelial cells in benign breast tissue with ﬁbroadenoma. (C) Mamoplasty sample tissue showing none labeling with
FAbC4. (D) Negative control of immunohistochemistry assay. (E–H) None immunoreactivity was observed in other cancer types, such as prostate, stomach, pancreas and
lymphoma. Counterstaining: Hematoxylin. Magniﬁcation: 200.
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ant room temperature for 2 h. The plates were washed 5 times with PBST. HRP-con-
jugated rat anti-HA antibody was added to each well (100 lL, 1:1000 dilution) and
the plates were incubated 1 h at room temperature. The plates were washed 5 more
times with PBST and revealed with 100 lL of o-phenylenediaminen substrate (Sig-
ma Aldrich). Reactions were stopped with 4 N of sulfuric acid, and the absorbances
read at 450 nm.
2.9. Puriﬁcation of soluble antibodies
The TOP10 E. coli non-suppressor strain was transformed with the positive
clone determined by ELISA, and used to inoculate SB culture containing 50 lg/
mL of carbenicillin and 2% glucose, which was grown under agitation at 37 C
overnight. Then, 2 mL were diluted in 200 mL of supplemented carbenicillin SB
medium, and incubated for 6–8 h under agitation (250 rpm) at 37 C, followed
by a centrifugation at 3000g for 10 min at 4 C. Bacteria were resuspended in
1000 mL in supplemented carbenicillin SB medium, and induced with 2.0 mM
IPTG at 30 C overnight. The cultures were then centrifuged at 3000g for
20 min to pellet bacterial cells. The supernatant was used for puriﬁcation of Fabsoluble antibodies by HPLC (Amersham Biosciences) according to the manufac-
turer’s instructions. Positive fractions were pooled and their concentrations were
obtained spectrophotometrically by absorbance readings at 260 (A1) and 280 nm
(A2) according to the following formula: [protein] = K3  A2  K4  A1; where
K3 = 1552, and K4 = 757.3. The samples were desalted by a Centriprep column,
lyophilized and resuspended in PBS/BSA1%.2.10. Sequence analysis
Phagemid DNA from positively selected clones and from the original library was
sequenced using the MegaBACE 1000 automatic sequencer (Molecular Dynamics).
The sequencing reactions were prepared with speciﬁc reverse primers MMB5 (50
CGTTTGCCATCTTTTCATAATC 30) for VH and MMB4 (50
GCTTCCGGCTCGTATGTTGTGT 30) for Vj genes. V gene sequence determinations
were based on Phred base calling [25] and chromatograms were used for manual
veriﬁcation of sequence ambiguities. Sequence alignments and translations were
made with the program BlastX. V gene families were assigned using the Ig-Blast ser-
Table 2
FabC4 expression detected by immunohistochemistry in breast tumor samples and
the clinical-histopathological variables (N = 232).
Variable N FabC4 P-Value
Negative N (%) Positive N (%)
Age (years) 0.04a
<40 34 6 (17.6) 28 (84.2)
40–60 110 33 (30.0) 77 (70.0)
>60 88 32 (36.4) 56 (63.6)
Menopausal status 0.77
Pre 98 29 (29.6) 69 (70.4)
Post 134 42 (31.3) 92 (68.7)
ER 0.09
Positive 134 46 (34.3) 88 (65.7)
Negative 84 20 (23.8) 64 (76.2)
PgR 0.01
Positive 93 37 (39.8) 56 (60.2)
Negative 127 30 (23.6) 97 (76.4)
HER-2 1.00b
Positive 22 6 (27.3) 16 (72.7)
Negative 166 49 (29.5) 117 (70.5)
Histological grading <0.001
GI 44 18 (40.9) 26 (59.1)
GII 127 46 (36.2) 81 (63.8)
GIII 61 7 (11.5) 54 (88.5)
Breast cancer subtypes 0.05
ER-/PgR-/HER-2- 48 9 (18.8) 39 (81.3)
ER-/PgR-/HER-2+ 16 3 (18.8) 13 (81.3)
Luminal 148 52 (35.1) 96 (64.9)
Tumor size (cT) 0.24
T1 19 6 (31.6) 13 (68.4)
T2 101 35 (34.7) 66 (65.3)
T3 8 9 (18.8) 39 (81.3)
T4 64 21 (32.8) 43 (67.2)
Lymph node (cN) 0.26
N0 74 19 (25.7) 55 (74.3)
N1–3 158 52 (32.9) 106 (67.1)
Distant metastasis (cM) 1.00
M0 212 65 (30.7) 147 (69.3)
M1 20 6 (30.0) 14 (70.0)
Recurrence 0.30
Yes 118 33 (28.0) 85 (72.0)
No 111 38 (34.2) 73 (65.8)
Death 0.16
Yes 113 30 (26.5) 83 (73.5)
No 117 41 (35.0) 76 (65.0)
Breast cancer 232 71 (30.6) 161 (69.4) 0.0002a
Benign breast disease 34 21 (61.8) 13 (38.2)
Ovary cancer 3 3 (100.0) 0
Lymphoma 3 3 (100.0) 0
Pancreas 3 3 (100.0) 0
Prostate 3 3 (100.0) 0
Stomach 3 3 (100.0) 0
Signiﬁcant values (P < 0.05) are in bold.
HER-2, human epidermal growth factor receptor-2; ER, estrogen receptor; PgR,
progesterone receptor.
a Chi-square for trend.
b Fisher exact test.
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framework region assignments were based on Kabat deﬁnition (www.bioinf.org.uk/
abs/). Only high quality sequences were used for translation.
2.11. Immunohistochemistry
After Fab selection, the afﬁnity of mammary tissue epitopes was veriﬁed by
immunohistochemical localization. Additional samples of breast adenocarci-
noma, breast ﬁbroadenoma and normal breast from mamoplasties were pro-
cessed and submitted to immunohistochemistry analyses, which were carried
out by the following steps: sections were incubated with citrate buffer 6 M for
1 h at 90 C for antigen retrieval. The peroxidase blockage was performed with
H2O2 3% in water for 30 min followed by blockage of unspeciﬁed sites with
PBS/BSA 10% for 1 h at room temperature. Then, the Fab addition (1:25) in tissue
sections was sequentially performed at 4 C overnight. Control sections were
incubated only with PBS. Immunoafﬁnity was analyzed by a mouse anti-HA con-
jugated to horseradish peroxidase (Sigma, 1:200 in PBS) for 1 h at room temper-ature. Slides were then revealed with diaminobenzidine substrate solution,
counterstained with hematoxylin and observed in a light microscope (Olympus
BX40). The photomicrographs were made by the software HLImage (Western Vi-
sion Software, USA).
2.12. Immunoprecipitation and protein sequencing
We performed immunoprecipitation of FabC4 using Mouse Anti-His mAb Mag
Beads (GenScript) according to manufacturer’s instructions. Bound proteins were
precipitated out of solution using the ProteoExtract kit (Calbiochem) and the pro-
tein pellet was left to dry overnight in a sterile fumehood. The lyophilized pellet
was then resuspended in 50 mM Ammonium bicarbonate (pH 8.0) and subjected
to an in-solution tryptic digestion (Mike Myers, Cold Spring Harbor modiﬁed by
Brett S. Phinney, UC Davis Proteomics Core). Digested peptides were then de-salted
using aspire tips (Thermo-Fisher Scientiﬁc, RP30 tips) before being resuspended in
loading buffer.
Digested peptides were analyzed using a LTQ-FT (Thermo Fisher Scientiﬁc) cou-
pled with a MG4 paradigm HPLC (Michrom, Auburn, CA). The samples were loaded
onto a Michrom cap trap (0.5  2 mm) to be de-salted. The peptides were then sep-
arated using a Michrom Magic C18AQ (200 lm  150 mm) reversed-phase column,
and eluted using a gradient during a period of 60 min. Collision induced dissocia-
tion was applied to the peptide samples and data was acquired with an isolation
width of 1, a normalized collision energy of 35 and a resolution of 50,000. The spray
voltage on the Michrom captive spray was set to 1.8 kV with a heated transfer cap-
illary temperature of 200 C.
Raw data was analyzed using XTandem and visualized using Scaffold (Proteome
Software, version 3.01). Samples were searched against Uniprot human (130,611
sequences) database appended with the cRAP (commonly found laboratory con-
taminants) and the reverse decoy databases.
2.13. Breast cancer sampling for Fab validation
To validate the FabC4, a population of BC patients’ samples (N = 232) with long-
term follow-up were obtained from A.C. Camargo Cancer Hospital (São Paulo, Bra-
zil) and evaluated by immunohistochemistry in a previously constructed tissue
microarray [26]. Patients were followed prospectively with a mean follow-up of
88.5 ± 63.1 months (3–227 months). All samples were from untreated patients be-
fore surgery. Patient’s characteristics are described in Table 1.
2.14. Statistical analysis
The efﬁcacy of selected clones in discriminating BC vs controls was tested by
ELISA assays (in the absence of an arbitrary cutoff value). The data is summarized
in ROC (receiver operating characteristic) curves, which were plotted by using the
sensitivity (true positives) on the Y-axis against 1 – speciﬁcity (false positives) on
the X-axis, considering each observed value as a possible cutoff value. The AUC (area
under the curve) was calculated as a single measure for the discriminative efﬁcacy
of the marker. When a marker has no discriminative value, the ROC curve will lie
close to the diagonal and the AUC is close to 0.5. When a test has strong discrimi-
native value, the ROC curve will move up to the upper left-hand corner and the AUC
will be close to 1.0. The chi-square test (or Fisher exact) was applied to determine
the strength of association between the categorical variables. Disease-free survival
(DFS) and overall survival (OS) probabilities were calculated using the Kaplan–Me-
ier method. The end-point for OS analysis was restricted to death due to breast can-
cer, and the end-point for DFS analysis was distant metastasis diagnosis. Stage IV
patients were excluded from these analyses. Kaplan–Meier survival curves for
FabC4 were also calculated in BC patients stratiﬁed according to molecular proﬁle
status. Multivariate analysis was carried out using Cox proportional hazards model.
The following variables were included in the multivariate model according to their
biological context relating to BC: age, ER, PgR, HER-2, histological grade, cT, cN, che-
motherapy, hormonal therapy, radiation treatment as well as the FabC4 status.
Additionally, variables with a p-value <0.2 in the univariate analyses also entered
in the multivariate model. The statistical analyses were carried out using SPSS ver-
sion 15.0 (SPSS; Chicago, IL) for Windows.3. Results
3.1. Library characterization
Eighty V sequence regions were analyzed and, although all the
clones in the library bear a full length insert, only 76% of them pre-
sented a functional VH/VL Fab fusion, resulting in a functional li-
brary size of 1.7  106.
The variable regions were derived from nine different V gene
families, including ﬁve VH gene families (VH1, VH2, VH3, VH4
and VH5) and four VL subgroups (Vj1, Vj3, Vj4 and Vj5). The
Table 3
Disease-free survival and overall survival analyses of TNM stage I–III triple negative breast cancer patients (N = 42).
Variable N DFS P OS P*
5 years (%) 10 years (%) 5 years (%) 10 years (%)
Age (years) 0.652 0.691
<40 8 37.5 37.5 37.5 37.5
40–60 24 52.9 36.1 57.4 41.8
>60 10 30.0 30.0 30.0 30.0
Menopausal status 0.636 0.667
Pre 24 40.0 31.1 44.1 35.3
Post 18 50.0 42.9 50.0 42.9
Histological grading 0.872 0.950
G1 1 100 0.0 100 0.0
G2 19 41.4 41.4 46.3 40.5
G3 22 44.1 33.0 43.5 38.0
Tumor size (cT) 0.019 0.054
T1 4 25.0 25.0 25.0 25.0
T2 14 55.6 46.3 53.4 44.5
T3 15 53.3 53.3 60.0 52.5
T4 9 22.2 0.0 22.2 11.1
Lymph node (cN) 0.320 0.333
N0 12 54.7 41.0 53.5 53.5
N1–3 30 40.0 32.3 42.9 31.7
EGFR 0.568 0.503
Positive 4 50.0 50.0 50.0 50.0
Negative 36 46.5 35.3 48.7 26.9
CK5/6 0.655 0.682
Positive 9 44.4 44.4 38.9 38.9
Negative 32 46.7 36.1 49.8 28.8
P63 0.068 0.095
Positive 6 16.7 16.7 16.7 16.7
Negative 35 53.6 39.1 52.7 42.3
FabC4 0.010 0.020
Positive 34 51.8 40.3 51.2 43.8
Negative 8 12.5 12.5 25.0 12.5
Signiﬁcant values are in bold.
DFS, disease-free survival; OS, overall survival.
* P-Values obtained by log-rank test.
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nance of the VH3 family with no Vj2 ampliﬁcation was observed,
and VH and VL sequences of CDR3 were highly diverse. Thus, the
Fab gene fragments were distributed across the full repertoire of
antibody germline genes.
Among selected clones, 98% of them encoded full-length, func-
tional Fab molecules as determined by slot-blot and sequencing
analyses (data not shown). In the slot-blot analysis, the presence
of Fab in the induced culture supernatants was detected using
HRP-conjugated anti-HA-HRP (Fig. 3A). Out of 95 clones tested,
93 showed a positive signal. In order to conﬁrm the presence of
Fab fragments, four randomly selected induced supernatants were
separated by SDS–PAGE under reduced conditions and blotted onto
nitrocellulose membrane. Detection of heterologous immunoglob-
ulin was demonstrated by HRP-conjugated monoclonal anti-HA
antibody immunostaining. The complex proﬁle observed in SDS–
PAGE may indicate bacterial lyses during culturing due to the
Fab toxicity (Fig. 3B). As expected, the Fab presented a calculated
molecular mass of 56 kDa, which is a result of the disulﬁde bond
dissociation in reduced conditions, generating two 28-kDa chains,
as demonstrated by the western blot analysis (Fig. 3C). Sequencing
analysis revealed different sequences for these induced clones.3.2. ELISA screening and puriﬁcation of the selected clone
The speciﬁcity of the selected soluble Fab’s against breast can-
cer antigens was determined by ELISA assays. Eight clones demon-
strated differential reactivity to the pool of proteins extracted from
normal, benign tumor and breast cancer tissues (Fig. 4A). All of
them discriminated, by ANOVA test, benign from breast cancertissues. Only the D12 clone could not differentiate normal from
BC samples. Nevertheless, only the FabC4 clone was selected for
further analyses, based on its highest reactivity ratios between
cancer/benign and cancer/normal (Fig. 4B). No positive signal
was observed in the negative control (pComb3X without insert).
The selected clone was ampliﬁed and its phagemid was used to
transform TOP10 E. coli non-suppressor strain, which was required
to express soluble Fab molecules without the fused pIII protein and
in high concentrations for HPLC puriﬁcation. After each sample
fractionation, 500 lL of the eluted solution were collected. The
tubes with the highest concentration were pooled and concentra-
tion was calculated by spectrophotometric readings. The yield of
puriﬁed Fab was 0.3 g/L. Samples were desalted by a Centriprep
column, lyophilized and ressuspended in PBS/BSA1%.3.3. FabC4. target identiﬁcation and tissue microarray analysis
The antigen corresponding to the FabC4 antibody was charac-
terized as Cytokeratin 10 (CK10) by immunoprecipitation experi-
ments and mass spectrometry.
In order to characterize the FabC4 binder, we have performed a
magnetic capture to both breast tumor and benign tissue antigens
with the conjugated FabC4 to magnetic nanoparticles. This immu-
noprecipitation was submitted to mass spectrometry analysis,
which was interpreted by removing the most prevalent contami-
nants, such as hemoglobin, albumin and actin. To restrict the num-
ber of putative targets, we have set 20% protein coverage with at
least 10 peptide matches per target in tumor tissues. We have used
the immunohistochemistry staining intensity for both groups to
validate the proportion observed in the protein coverage and
Fig. 7. Disease-free survival and overall survival curves according to FabC4
immunoreactivity. P values were determined by log-rank test.
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For tumor tissues, we detected three potential targets (CK1, CK9
and CK10), which were also observed in benign tissues, but in dif-
ferent proportions (Fig. 5). Since CK1 (Fig. 5A) and CK10 (Fig. 5C)
form a heterodimer and they were the most prevalent in tumor tis-
sues with the highest matches, we discarded the CK9 (Fig. 5B) as a
target. CK1 was additionally eliminated from our potential target
due to its greater coverage and number of peptide matches ob-
served in benign tissues, a result incompatible with the immuno-
histochemistry data. Therefore, a recombinant CK10 (Abnova)
was obtained and submitted to ELISA with FabC4, which showed
a strong positive reactivity, similar to the reaction observed for
BC tissue proteins and signiﬁcantly different (P < 0.01) from
expression levels found in the other two groups (Fig. 4C). Evidences
also suggest that the speciﬁc ligand of the FabC4 antibody is a con-
formational epitope of the CK10, as shown by negative western
blot and positive ELISA results (data not shown).
Immunohistochemistry data of the FabC4 is also displayed in
Fig. 6. Immunostaining was signiﬁcantly higher (P = 0.0002) in BC
compared to benign tumor, and increased expression levels were
correlated with the invasive breast cancer tumors in comparison
to benign and normal breast tissues. Strong labeling was observed
in the ducts of invasive carcinoma (Fig. 6A), while the benign sec-
tion showed a moderate immunoreactivity (Fig. 6B), and no label-
ing was observed in normal breast tissue (Fig. 6C) and reaction
control sections (Fig. 6D). Moreover, no or weak cross-reactions
of the FabC4 with other cancer tissue types, such as prostate, stom-
ach, pancreas and lymphoma were observed (Fig. 6E–H).3.4. FabC4 immunoreactivity in breast cancer and clinical-
histopathological variables
Negative association between age at diagnosis and FabC4
immunoreactivity rates was observed (P = 0.04), since 84.2% of
BC patients <40 years had FabC4 expression in comparison with
63.6% of positivity from BC patients >60 years old (Table 2). Pa-
tients with absence of ER and PgR expression had higher percent-
age of FabC4 positivity, although only PgR analysis reached
statistical signiﬁcance (P = 0.09 and P = 0.01, respectively, Table 2).
Histological grades were clearly associated with FabC4, since its
positivity rates were 59.1%, 63.8%, and 88.5% in GI, GII, and GIII
BCs, respectively (P < 0.001, Table 2). Regarding the molecular pro-
ﬁle classiﬁcation, luminal BCs presented lower FabC4 immunore-
activity in comparison with non-luminal tumors. On the other
hand, we could not observe any difference between Her2-enriched
and TNBC (Table 2). Regarding menopausal status, HER-2 protein
expression, and initial TNM stage, no statistical signiﬁcant associa-
tions were observed (Table 2).3.5. FabC4 immunoreactivity and breast cancer outcomes
No association was observed between FabC4 immunoreactivity
and DFS and OS analysis. As expected, signiﬁcant associations were
detected between the clinical outcome and the established prog-
nostic factors (nodal status, clinical stage, histological grade, ER
and PgR status, and molecular proﬁle).
Multivariate analysis demonstrated that tumor size (cT) and
lymph node status (cN) were the only independent prognostic fac-
tors for DFS (HR: 1.80; 95% CI: 1.36–2.26; P < 0.001 and HR: 2.20;
95% CI: 1.26–3.75; P = 0.005, respectively). Regarding OS, in addi-
tion to cT (HR: 1.7; 95% CI: 0.27–2.16; P < 0.001) and cN (HR:
1.9; 95% CI: 0.09–3.34; P = 0.023), histological grade also presented
independent prognostic impact (HR: 1.50; 95% CI: 0.03–2.18;
P = 0.032).
BC patients were stratiﬁed according to immunohistochemical
subtypes (luminal vs. HER2-enriched vs. TNBC) and Kaplan–Meier
survival curves were calculated. No prognostic impact was ob-
served regarding the FabC4 status in the groups of luminal and also
in the HER2-enriched BCs (data not shown).
However, in the group with TNBCs, FabC4 status could differen-
tiate cases with distinct outcomes. Tumors with FabC4 expression
showed signiﬁcantly increased DFS and OS (P = 0.01 and P = 0.02,
respectively, Table 3 and Fig. 7). The median DFS of TNBCs was
13 months and 74 months in the groups with negative and positive
FabC4, respectively. Furthermore, median OS was 21 months and
84 months, in the groups with negative and positive FabC4,
respectively.
Multivariate analysis on the TNBC cases (N = 42) demonstrated
that FabC4 status is an independent prognostic factor for DFS and
probably for OS. Lower risk of metastasis due to the disease was
observed in FabC4-positive tumor patients (HR = 0.146, 95% CI
0.042–0.514, P = 0.003), and also those submitted to radiotherapy
(HR = 0.151, 95% CI 0.036–0.643, P = 0.011). On the other hand, pa-
tients submitted to chemotherapy (HR = 6.567, 95% CI 1.407–
30.649, P = 0.017) and those with tumors expressing the P63 pro-
tein (HR = 8.596, 95% CI 1.197–33.638, P = 0.002) presented lower
DFS. Regarding OS, the only variable retained in the ﬁnal model
was radiotherapy (HR = 0.283, 95% CI 0.081–0.991, P = 0.048).4. Discussion
Breast cancer (BC) is a heterogeneous disease, encompassing a
wide variety of histological types and clinical behaviors. Current
histological classiﬁcation systems for breast cancer are based on
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predictive biomarkers are currently available, we have used the
phage display technology and a newly constructed Fab antibody
combinatorial library from breast cancer tissues to select a novel
antibody that was not only capable of improving BC diagnosis,
but could also be used as for prognostics, which to our best of
knowledge there is no such a marker [3]. Most important, only re-
cently [27] two tissue biomarkers (ubiquitin and truncated S100P)
were used in combination to discriminate breast cancer from
healthy tissues, but the publication failed to present any diagnostic
parameter (sensitivity and speciﬁcity).
We have successfully selected a reactive antibody, FabC4, with
good sensitivity (70%) and speciﬁcity (62%) for diagnosis, good cor-
relation with disease staging due to its increased expression during
disease progression, and association with a subset of triple nega-
tive BCs with good prognosis. The FabC4 targets the Cytokeratin
10 (CK10) protein, and the determinant region seems to be recog-
nized as a speciﬁc conformational epitope in breast cancer.
The FabC4-ligand is breast speciﬁc, and its presence in some pa-
tients with benign diseases may be an indication of a pre-neoplas-
tic disease without signiﬁcant morphology alterations. On the
other hand, the absence of the biomarker in tumor tissues may
be due to the heterogeneity of the disease and some of the altera-
tions cannot be explained by post-translational modiﬁcations of
the CK10.
The possible recognition of a CK10 conformational epitope
raises a fundamental question whether CK10 post-translational
modiﬁcations may present different biological roles in breast
cancer. This interﬁlament can bind to several other proteins, such
as protein kinases (PKC, PKB) and Akt, which can regulate the
cell cycle machinery, and present speciﬁc interactions in breast
cancer. The role of the cytokeratins, including CK10, has no long
been thought to be only structural, as this single function does
not explain their diverse tissue and speciﬁc expression patterns
[28,29].
This is the ﬁrst potential biomarker for breast cancer diagnosis
and histological classiﬁcation linked to a CK10 epitope. Interest-
ingly, CK10 has been associated with other cancers, and is one of
the most common proteins in lymphatic metastases of cancers re-
vealed by proteomic and protein functional studies [30]. CK10 has
also been associated with poor prognosis in hepatocellular carci-
noma regardless of tumor-node-metastasis stage, and vascular
invasion [31] and with invasive carcinomas, in which the expres-
sion of keratin 10 was signiﬁcantly associated with keratinizing
carcinomas [32]. But because of the high speciﬁcity found in breast
tissues in our study, we cannot rule out the possibility that confor-
mational changes in CK10 may be associated with loss of function,
as demonstrated in a CK10-null mouse model elsewhere [33],
which has shown that CK10 is downregulated in squamous cell
carcinomas and it is absent in proliferating cells in vivo, linking
CK10 functions to both cellular architecture and cell cycle control.
At present, a causal role in tumorigenesis is not established for any
keratin, and additional studies must be done to elucidate CK10
function in breast cancer. Furthermore, the identiﬁcation of keratin
associated proteins and the analysis of keratin phosphorylation are
beginning to provide insights into the molecular mechanisms by
which they act, once reorganization of keratin IFs in response to
extra- or intracellular signals predominantly involves phosphory-
lation events [34].
Phage antibody library has been used before to generate high-
afﬁnity antibodies against previously deﬁned tumor-associated
antigens such as-CEA and c-erb-2 [35–37], but were performed
against speciﬁc ligands, different from our subtractive approach
with unknown antigen target, which resulted in several tissue
markers. The selected FabC4 presented an overall accuracy of61%, but its expression was increased during cancer development
and reached a positivity of 88.5% in advanced BC stages.
Because our antibody showed a gradual immunoafﬁnity accord-
ing to histopathological grade of mammary gland ducts with inva-
sive carcinoma, and the CK10 epitope ligand showed signiﬁcant
protein expression in tumor tissues when compared to benign and
normal tissues, it is expected that CK10 may also show differential
expression during cancer progression with high tissue immunoreac-
tivity to undifferentiated ducts, and weak or no reactivity to differ-
entiated ducts from inﬁltrative adenocarcinoma or normal tissue
from mammoplasty. The low expression in normal tissues may be
due to the lack of post-translational modiﬁcations, which may play
a critical role in the malignant transformation.
Challenging situations of metastatic cancers with unknown pri-
mary is very common, and deserves the utilization of breast-speciﬁc
markers for differentiating BC from non-breast tissues. In this sense,
ER, mammaglobin and gross cystic disease ﬂuid protein-15 (GCDFP-
15) are widely accepted biomarkers for immunohistochemistry [38].
Cases of metastatic TNBC are even more difﬁcult for the pathologist,
since those markers are less expressed [39].
ER, PR, HER-2, and Ki-67 protein expression are routinely eval-
uated in order to classify BCs into different subtypes, namely lumi-
nal A, luminal B, HER-2-enriched and TNBC [40]. Though widely
used in clinical practice these biomarkers are not capable to cap-
ture the complexity of BC. TNBC represents a subset of aggressive
tumors accounting for 15% to 20% of newly diagnosed BC cases
[41]. Potential therapeutic targets are likely to be identiﬁed while
the heterogeneity of TNBC is better deﬁned [42]. In the present
study, FabC4 clone was associated with more aggressive tumors;
i.e., those younger patients, with lack of PgR expression, higher his-
tological grades and non-luminal BCs. Interestingly, in the subset
of known aggressive TNBCs, FabC4 was a good prognostic marker.
The major limitation of our study is regarding the sub-analysis
of FabC4 prognostic impact in TNBCs, since the number of patients
evaluated was very small. However, it was observed a very low
hazard rate for DFS (HR = 0.146) after multivariate analysis. Even
considering the possible bias related to the small sample size, our
ﬁndings suggest that the prognostic impact of FabC4 merits further
evaluation in the TNBC patients.
In conclusion, the CK10-epitope speciﬁc Fab antibody is the ﬁrst
diagnostic and prognostic speciﬁc breast tissue biomarker, which
can be used for BC diagnosis and staging, and it was also associated
with a subset of triple negative BCs with good prognosis. Its role in
BCs should be addressed in future studies.Conﬂict of Interest
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